^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Breyanzi (lisocabtagene maraleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Published date:
09/01/2020
Excerpt:
Eligible histological subgroups included diffuse large B-cell lymphoma, high-grade B-cell lymphoma with rearrangements of MYC and either BCL2, BCL6, or both (double-hit or triple-hit lymphoma), diffuse large B-cell lymphoma...objective response was achieved by 186 (73%, 95% CI 66·8–78·0) patients and a complete response by 136 (53%, 46·8–59·4)...
DOI:
https://doi.org/10.1016/S0140-6736(20)31366-0
